• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » KalGene Pharmaceuticals forms multi-year collaboration for aggressive cancers

KalGene Pharmaceuticals forms multi-year collaboration for aggressive cancers

June 13, 2014
CenterWatch Staff

KalGene Pharmaceuticals, a developer of a prognostic marker and companion therapeutic that specifically targets aggressive cancers, has formed a multi-stage and multi-year collaboration with the Center for Imaging Technology Commercialization (CIMTEC), Sunnybrook Research Institute (SRI) and the Ontario Cancer Biomarker Network (OCBN) at Queen's University.

Dr. Nathan Yoganathan, president and chief scientific officer at KalGene, said, “We are developing precision medicine tools that provide more effective cancer therapeutics that also will significantly alleviate patient suffering during treatment and improve overall quality of life."

Precision medicine seeks to predict which patients will respond to a particular therapy in advance of treatment. This allows physicians to prescribe treatment only to the individuals most likely to benefit.

KalGene has several projects in its pipeline, ranging from early stage research to clinical trials. The current project focuses on metastatic disease, an unmet medical need for breast, colon and brain cancer. KalGene's principals, Dr. John Gillard and Yoganathan, believe they have a unique solution and are enlisting the experience of Canadian and international partners.

CIMTEC is providing project management services and coordinating research laboratories in multiple cities. In addition, its engineers are creating digital pathology algorithms to quantify new biomarkers.

Sunnybrook Research Institute's Biomarker Imaging Research Laboratory (BIRL) is providing experience in optimizing multiplexed immunohistochemistry imaging and characterizing the structure and function of specific antibodies to develop a therapeutic that targets aggressive cancers.

OCBN, through its laboratory operations at Queen's University under the direction of Dr. Harriet Feilotter, is further contributing to the optimization of IHC staining and providing avenues for clinical review.

Upcoming Events

  • 24May

    Powering an Effective Oversight Strategy with Clinical and Operational Insights

  • 25May

    2022 WCG Avoca Quality & Innovation Summit: Own the Future

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing